8 August 2017
In December 2013 the first results of IBIS-II Prevention were published. They showed that women on anastrozole more than halved their chances of developing the disease compared to those on placebo. Although participants on anastrozole suffered more joint, bone and muscle aches and hot flushes, these side effects were less than expected in comparison to other research studies on anastrozole and only slightly more common than for women on placebo.
These results provide us with crucial information about the effects of anastrozole in preventing breast cancer in post-menopausal women at high risk of the disease. It is hoped that this will lead to a change in clinical practice with anastrozole being routinely prescribed as a preventative medicine.
Coverage and more information can be read on: